News

Novo Nordisk A/S’s weight-loss shot Wegovy gained expanded clearance as a heart drug in the UK, as the country’s regulators followed the US in broadening use of the blockbuster medicine.
More medicines will be spared from Medicare price negotiations, a change that is projected to wipe out billions in savings ...
Novo Nordisk announces collaboration with WeightWatchers to offer patients living with obesity access to FDA-approved Wegovy ...
Regeneron said on Monday its experimental drug helped patients preserve up to 51% of lean mass and lose more fat when used in combination with Novo Nordisk's popular obesity drug Wegovy in a mid-stage ...
New rules are reshaping the telehealth market for GLP-1s like Ozempic and Wegovy, potentially impacting access to these drugs ...
Drugmaker Novo Nordisk said it is halting its agreement with telehealth company Hims & Hers after less than two months, ...
Legal wins build on 111 lawsuits filed by Novo Nordisk across 32 states against entities unlawfully marketing and selling compounded "semaglutide" drugs, ... FDA-approved Wegovy ...
Novo Nordisk continues to expand its partnerships with telehealth companies to broaden access to its blockbuster weight loss drug Wegovy. | Novo Nordisk is partnering with WeightWatchers to offer ...
When the FDA declared the shortage resolved for semaglutide, the main pharmaceutical ingredient in Wegovy and Ozempic, the agency gave 503B facilities until May 22 to stop making compounded versions.
CVS Health on Thursday said it will significantly expand access to the blockbuster weight loss drug Wegovy for patients covered by its pharmacy benefit manager, Caremark. Starting July 1, Caremark ...
A federal court in Texas reportedly dismissed a bid by drug compounders to continue producing off-brand versions of Novo Nordisk‘s weight-loss drug Wegovy and diabetes treatment Ozempic while a ...
Novo Nordisk says oral version of Wegovy accepted for FDA review. May 02, 2025 2:50 PM ET ... Subject to FDA approval of the company's new ... marking the first late-stage trial win for the GLP-1 ...